Lantus

Mylan, Biocon copy inches closer to challenging Sanofi's long-suffering Lantus
Mylan, Biocon copy inches closer to challenging Sanofi's long-suffering Lantus
Fierce Pharma
Sanofi
Lantus
Eli Lilly
Boehringer Ingelheim
Mylan Labs
generics
diabetes
insulin
basal insulin
Flag link:
Merck ditches biosimilar Lantus, but will that ease the path for Mylan’s rival insulin product?
Merck ditches biosimilar Lantus, but will that ease the path for Mylan’s rival insulin product?
Fierce Pharma
Merck
Samsung Bioepis
Lantus
insulin
diabetes
biosimilars
Mylan Labs
Biocon
Flag link:
Mylan Announces IPR Proceedings for Sanofi's Lantus Patents
Mylan Announces IPR Proceedings for Sanofi's Lantus Patents
Yahoo/Zacks.com
Mylan Labs
inter partes review
Sanofi
Lantus
patents
diabetes
Flag link:
Sanofi sues Mylan over Lantus patents, seeking to defend its top-selling drug
Sanofi sues Mylan over Lantus patents, seeking to defend its top-selling drug
Fierce Pharma
Sanofi
Mylan Labs
Lantus
patents
insulin
biosimilars
diabetes
Flag link:
EASD: Sanofi's Toujeo bests Lantus at holding off hypoglycemia, studies show
EASD: Sanofi's Toujeo bests Lantus at holding off hypoglycemia, studies show
Fierce Pharma
Sanofi
EASD
Toujeo
Lantus
hypoglycemia
diabetes
Flag link:
The decade's top 10 patent losses, worth a whopping $915B in lifetime sales
The decade's top 10 patent losses, worth a whopping $915B in lifetime sales
Fierce Pharma
patents
AbbVie
Humira
Pfizer
Lipitor
Norvasc
GSK
Advair
Sanofi
Lantus
JNJ
Remicade
AstraZeneca
Crestor
Nexium
Amgen
Neulasta
Novartis
Diovan
Flag link:
Sanofi brings another insulin glargine patent suit against Merck
Sanofi brings another insulin glargine patent suit against Merck
Drug Delivery Business News
Sanofi
patents
Merck
insulin glargine
Lantus
Flag link:
Despite scoring an FDA nod, Merck's biosim Lusduna must wait to challenge Lantus
Despite scoring an FDA nod, Merck's biosim Lusduna must wait to challenge Lantus
Fierce Pharma
FDA
Merck
biosimilars
Lusduna Nexvue
Lantus
diabetes
Sanofi
Hatch Waxman Act
Flag link:
The 9 Best-Selling Prescription Drugs in 2016 (Each One Topped $6 Billion)
The 9 Best-Selling Prescription Drugs in 2016 (Each One Topped $6 Billion)
Motley Fool
prescription data
Sanofi
Lantus
Roche
Herceptin
Avastin
Celgene
Revlimid
JNJ
Merck
Remicade
Biogen
Rituxan
Amgen
Enbrel
Gilead Sciences
Harvoni
AbbVie
Humira
Flag link:
Novo Nordisk files to add Lantus-matching CV data to Tresiba's European label
Novo Nordisk files to add Lantus-matching CV data to Tresiba's European label
Fierce Pharma
Novo Nordisk
Lantus
Tresiba
diabetes
Europe
EMA
insulin
Flag link:
ADA preview: 5 things to watch in diabetes
ADA preview: 5 things to watch in diabetes
BioPharma Dive
ADA
diabetes
Jardiance
Eli Lilly
Boehringer Ingelheim
Lantus
Tresiba
JNJ
Novo Nordisk
PCSK9 inhibitors
Amgen Regeneron
Sanofi
Apple
Google
insulin
Flag link:
Top 10 diabetes drugs by 2016 sales
Top 10 diabetes drugs by 2016 sales
Fierce Pharma
diabetes
Sanofi
Novo Nordisk
Eli Lilly
Merck
Lantus
Januvia
Victoza
Levemir
Humalog
Novolog
Invokana
Flag link:
Sanofi enjoys solid Q1, despite continuing erosion of Lantus sales in U.S.
Sanofi enjoys solid Q1, despite continuing erosion of Lantus sales in U.S.
Fierce Pharma
Sanofi
earnings
diabetes
Lantus
Flag link:
Sanofi May Now Have Moved Past Its Most Challenging Period, Analyst Initiates At Buy
Sanofi May Now Have Moved Past Its Most Challenging Period, Analyst Initiates At Buy
Yahoo/Benzinga
Sanofi
Lantus
Plavix
patents
Flag link:
Could This Look-A-Like Drug Be Merck's Next Big Seller?
Could This Look-A-Like Drug Be Merck's Next Big Seller?
Motley Fool
MK-1293
Merck
diabetes
insulin
Lantus
biosimilars
Flag link:
Will Sanofi See More Growth from Its Blockbuster Insulin Drug?
Will Sanofi See More Growth from Its Blockbuster Insulin Drug?
Market Realist
Sanofi
insulin
diabetes
Lantus
Flag link:
Sanofi can’t even buy a break now, as rival Novo speeds ahead on diabetes showdown
Sanofi can’t even buy a break now, as rival Novo speeds ahead on diabetes showdown
Endpoints
Sanofi
Novo Nordisk
diabetes
Lantus
Xultophy
Flag link:
Merck Results Underscore Need To Go Big Or Go Home In Diabetes Market
Merck Results Underscore Need To Go Big Or Go Home In Diabetes Market
Forbes
Merck
diabetes
Sanofi
Januvia
Lantus
Flag link:
Eli Lilly Launches Lantus Biosimilar To Boost Sales, But Not Without Risks
Eli Lilly Launches Lantus Biosimilar To Boost Sales, But Not Without Risks
Seeking Alpha
Eli Lilly
Lantus
biosimilars
diabetes
Basaglar
Flag link:
Merck eyes US approval with positive data on Lantus copy
Merck eyes US approval with positive data on Lantus copy
BioPharma Dive
Merck
diabetes
Lantus
MK-1293
Sanofi
Flag link:

Pages